Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,482 total articles
Inspired Entertainment (INSE) looks materially undervalued relative to its cash generation and contract visibility. With a long-term retail extension with Paddy Power, regulatory wins in Alberta and improving technical momentum, the setup supports a long position. Entry $7.95, stop $6.80, target $11.00; position horizon 180 trading days.
Mako Mining looks primed for a re-rating as operational and exploration newsflow shifts the story from 'junior risk' to 'growth optionality.' We lay out an actionable long trade with entry, stop and target, plus catalysts and the risks that would flip our view.
XPeng's GX SUV launch is a tangible product catalyst that can re-accelerate deliveries and headline market interest. The stock trades at $17.30 with bullish technicals, constructive month-over-month delivery trends, and meaningful short interest. This trade targets a move back toward $24 over the next 45 trading days, with a protective stop at $15.
Microsoft remains the best-in-class SaaS/cloud compounder. Near-term sentiment has punished the name on worries about enterprise SaaS spending, but Azure's durable growth, healthy margins and a valuation that still embeds optimism for secular cloud adoption give a favorable asymmetric trade. This is a medium-risk, swing trade idea to buy a tactical…
Seanergy Maritime is trading at a market cap roughly in line with the company’s newbuilding tab while already locking in high Capesize time-charters. With a trailing P/E of 8.7, a 2.8% dividend yield and a clear fleet renewal program, the stock looks priced for a much weaker market than the company currently faces. We favor a disciplined long with …
L3Harris is a play for investors who want defense-sector downside protection with upside if contracts, launches, or program execution accelerate. The company generates $2.59B in free cash flow, carries moderate leverage (debt/equity ~0.58), and trades well inside a 52-week range after a recent pullback. Enter $310, stop $285, target $375 over a lon…
Ero Copper has more than doubled from its 2025 lows and is trading near $30.10. Strong copper market dynamics, improving production optionality in Brazil, a manageable valuation (market cap ~$3.14B, P/E ~10.8), and bullish technicals support a tactical long. We lay out an entry at $30.10, stop at $26.00, and a primary target of $38.00 over a mid-te…
Gorilla Technology (GRRR) just cleared several operational and commercial milestones that reframe it as a speculative AI infrastructure play. The stock is actionable as a swing trade on the back of a large GPU deployment pact in India and accelerating top-line cues, but short interest, regulatory noise, and execution risk make this a high-risk trad…
Take-Two is priced for a successful Grand Theft Auto VI launch but the underlying business has already shown traction: beat-and-raise results, $461.5M in free cash flow, and a bookings outlook lifted to $6.65-$6.7B. This trade targets a re-rating into the $280s while keeping a tight stop for execution risk.
Elevance Health looks positioned for an operational and multiple recovery. Strong Q1 results, raised guidance, healthy free cash flow and a reasonable P/E leave room for upside if CMS sanctions are resolved or moderated. We upgrade the rating and outline an actionable long-term trade with defined entry, stop and target.
Upstart (UPST) trades near $33.68 with more than 30% of the float sold short and a market cap of about $3.22B. The bears point to Model 22 headaches and legal noise. The bulls point to accelerating auto and mortgage originations, a manageable P&L, and a crowded short book that can force squeezes. This is a mid-term trade idea: entry $33.68, stop $2…
Nvidia's enterprise pivot from GPU supplier to full-stack AI infrastructure vendor has put it in the center of the next data-center and cloud spending wave. The company’s scale, cash generation and low leverage reduce execution risk, while new CPU and superchip announcements expand addressable markets. This trade idea outlines a long entry at curre…
Sea (SE) combines high-teens to mid-40s revenue growth with improving profitability and a fortress-like cash position. With a market cap near $56.8B, a P/S around 2x and recent record $1B adjusted EBITDA, Sea is an attractive GARP/PEG candidate for investors who can wait through execution risk. Actionable trade plan provided for a long-term (180 tr…
Meta is trading below where its fundamentals and cash-generation suggest it should. Strong free cash flow ($48.25B), a lean balance sheet (debt/equity ~0.24), and accelerating AI-driven product initiatives create a pathway for the market to remove the so-called 'Zuckerberg discount' and award a premium multiple. This is a long-term trade idea with …
Life360 accelerated monetization in Q1 2026—38% revenue growth, a quadrupling ad business to $19.7M after the Nativo acquisition, and a $225M buyback authorization. The combination of subscription momentum, ad expansion, positive free cash flow, and a conservative balance sheet supports a tactical long. Trade plan: enter at $43.69, stop $38.00, tar…
Magnachip has rallied from a $2.18 low to test a $9.67 52-week high after a Q1 that beat revenue estimates. The company’s MOSFETs, PMICs and power-management lineup give it asymmetric upside if AI and computing customers accelerate design wins. With a modest market cap (~$320M), clean balance-sheet ratios and an EV/Sales of ~1.5, this is a swing tr…
MGM Resorts is benefiting from stronger-than-expected Vegas tourism, attractive cash generation and a reasonable EV/EBITDA multiple. Technical momentum and heavy short interest add a tactical tailwind. Take a disciplined long with entry at $44.00, stop at $40.00 and a $52.00 target over a 45-trading-day swing.
Yum! Brands is a cash-generative QSR platform trading at a reasonable multiple while Pizza Hut faces a crossroads. With consumer trade-down dynamics favoring pizza, recent weakness in the stock and technically oversold conditions create a tactical long opportunity. This trade targets a recovery toward the high-$160s if Pizza Hut execution stabilize…
Taysha's TSHA-102 Rett program is on a faster path to potential approval, with dosing completion expected by Q2 2026 and FDA alignment on manufacturing and BLA strategy. That shortened timeline raises upside if data and filing go smoothly — but leaves little margin for safety or manufacturing setbacks. This trade idea lays out a long entry and expl…
GE HealthCare plunged after a Q1 earnings miss and a PDx supplier disruption. The sell-off opens a chance to buy a high-quality medical-equipment and diagnostics leader at about $28.4B market cap, with reasonable valuation metrics (P/E ~15, EV/EBITDA ~10). This trade idea lays out a disciplined long: entry $62.00, stop $58.75, target $75.00, horizo…
IonQ has become the poster child for commercially viable quantum computing after hitting technical milestones and benefiting from government funding for the sector. The stock is richly valued at a $26.9B market cap, but momentum, shrinking days-to-cover and concrete catalysts create a tradable mid-term opportunity. This trade idea lays out an entry…
Root, a telematics-first auto insurer, has moved from loss-making growth to profitability and now trades at modest multiples (market cap ~$824M, EV ~$427M, P/E ~15). With ROE near 17%, improving underwriting and an active short interest, the stock is a tradable swing setup. This trade idea buys a tactical dip for mid-term upside while capping downs…
TeraWulf is trading near its 52-week high after a sustained rerating driven by data-center expansion and investor appetite for crypto miners pivoting to AI infrastructure. The company carries clear execution and valuation risks, but recent financing, conference visibility, and bullish technicals make a measured long position attractive. Entry, stop…
Geron is a commercial-stage biotech with a growing oncology drug franchise (RYTELO). After a strong 2025 launch year ($184M net product revenue) and guidance for $220-240M in 2026, the stock trades near its 52-week low despite improving fundamentals. Technicals show oversold conditions and heavy short interest, creating a setup for a re-rating if c…
GTx-104's STRIVE-ON Phase 3 data show meaningful improvement in tolerability and dose intensity versus oral nimodipine. With a market cap near $40M and roughly $14.5M in cash on the balance sheet, Grace Therapeutics presents a high-risk, asymmetric opportunity. This trade plan targets a mid-term re-rating if regulatory clarity or partnership chatte…
